Top

Published in:

01-09-2015 | Mood Disorders (S Frangou, Section Editor)

Double-Blind Randomized Placebo-Controlled Trials in the Treatment of Affective Disorders: Problems and Alternatives

Authors: E. Severus, M.D., E. Laber, Ph.D., I. Lipkovich, Ph.D.

Published in: Current Treatment Options in Psychiatry | Issue 3/2015

Opinion statement

Double-blind randomized placebo-controlled trials, in which a new approval-seeking drug is compared to placebo, are generally considered to be the gold standard for evaluating the efficacy of a psychopharmacological intervention in the treatment of affective disorders. However, this type of study has substantial limitations regarding the external validity of its results. Therefore, alternatives within randomized controlled trials, such as non-inferiority trials or study designs in which the new drug or placebo is given simultaneously on top of standard antidepressant or anti-manic treatment are of substantial interest. In addition, innovative statistical approaches such as marginal structural models or Q-learning should be employed to evaluate potential causal effects associated with different fixed treatment regimes that are realized in actual clinical practice and help to establish treatment recommendations that are tailored to individual patient characteristics.

Wisniewski SR, Rush AJ, Nierenberg AA, Gaynes BN, Warden D, Luther JF, et al. Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report. Am J Psychiatry. 2009;166:599–607.PubMedCrossRef

Brody B, Leon AC, Kocsis JH. Antidepressant clinical trials and subject recruitment: just who are symptomatic volunteers? Am J Psychiatry. 2011;168:1245–7.PubMedCrossRef

Rutherford BR, Sneed JR, Roose SP. Does study design influence outcome? The effects of placebo control and treatment duration in antidepressant trials. Psychother Psychosom. 2009;78:172–81.PubMedCentralPubMedCrossRef

Sinyor M, Levitt AJ, Cheung AH, Schaffer A, Kiss A, Dowlati Y, et al. Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses. J Clin Psychiatry. 2010;71:270–9.PubMedCrossRef

Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol. 2009;19:34–40.PubMedCrossRef

Severus E, Seemuller F, Berger M, Dittmann S, Obermeier M, Pfennig A, et al. Mirroring everyday clinical practice in clinical trial design: a new concept to improve the external validity of randomized double-blind placebo-controlled trials in the pharmacological treatment of major depression. BMC Med. 2012;10:67.PubMedCentralPubMedCrossRef

Kelley JM, Kaptchuk TJ, Cusin C, Lipkin S, Fava M. Open-label placebo for major depressive disorder: a pilot randomized controlled trial. Psychother Psychosom. 2012;81:312–4.PubMedCrossRef

Bourin MS, Severus E, Schronen JP, Gass P, Szamosi J, Eriksson H, et al. Lithium as add-on to quetiapine XR in adult patients with acute mania: a 6-week, multicenter, double-blind, randomized, placebo-controlled study. Int J Bipolar Disord. 2014;2:14.PubMedCentralPubMedCrossRef

9.•

Wu F, Laber EB, Lipkovich IA, Severus E. Who will benefit from antidepressants in the acute treatment of bipolar depression? A reanalysis of the STEP-BD study by Sachs et al. 2007, using Q-learning. Int J Bipolar Disord. 2015;3:7. Clinically relevant application of Q-learning, in the context of the acute treatment of bipolar depression.PubMedCentralPubMedCrossRef

10.

Nahum-Shani I, Qian M, Almirall D, Pelham WE, Gnagy B, Fabiano GA, et al. Experimental design and primary data analysis methods for comparing adaptive interventions. Psychol Methods. 2012;17:457–77.PubMedCrossRef

11.

Nahum-Shani I, Qian M, Almirall D, Pelham WE, Gnagy B, Fabiano GA, et al. Q-learning: a data analysis method for constructing adaptive interventions. Psychol Methods. 2012;17:478–94.PubMedCentralPubMedCrossRef

12.

Schulte PJ, Tsiatis AA, Laber EB, Davidian M. Q- and a-learning methods for estimating optimal dynamic treatment regimes. Stat Sci. 2014;29:640–61.PubMedCentralPubMedCrossRef

13.

Shortreed SM, Laber E, Scott ST, Pineau J, Murphy SA. A multiple imputation strategy for sequential multiple assignment randomized trials. Stat Med. 2014;33:4202–14.PubMedCrossRef

14.

Goldberg Y, Kosorok MR. Q-learning with censored data. Ann Stat. 2012;40:529–60.PubMedCentralPubMedCrossRef

15.

Zhao YQ, Zeng D, Laber EB, Song R, Yuan M, Kosorok MR. Doubly robust learning for estimating individualized treatment with censored data. Biometrika. 2015;102:151–68.PubMedCrossRef

16.

Laber EB, Lizotte DJ, Ferguson B. Set-valued dynamic treatment regimes for competing outcomes. Biometrics. 2014;70:53–61.PubMedCentralPubMedCrossRef

17.

Laber EB, Zhao YQ, editors. Tree-based methods for individualized treatment regimes. In: Biometrika. 2015 (in press).

18.

Zhao YQ, Zeng DL, Rush AJ, Kosorok MR. Estimating individualized treatment rules using outcome weighted learning. J Am Stat Assoc. 2012;107:1106–18.PubMedCentralPubMedCrossRef

19.

Zhang BQ, Tsiatis AA, Laber EB, Davidian M. A robust method for estimating optimal treatment regimes. Biometrics. 2012;68:1010–8.PubMedCentralPubMedCrossRef

20.

Zhang Y, Laber EB, Tsiatis AA, Davidian M, editors. Using decision lists to construct interpretable and parsimonious treatment regimes. In: Biometrics. 2015. in press

21.

Zhang B, Tsiatis AA, Davidian M, Zhang M, Laber E, editors. Estimating optimal treatment regimes from a classification perspective. In Stat. 2012;1:103-114.

22.

Hernán MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology. 2000;11:561–70.

23.

Hernán MA, Brumback B, Robins JM. Marginal structural models to estimate the joint causal effect of nonrandomized treatments. J Am Stat Assoc. 2001;96:440–8.

24.

Hernán MA, Brumback BA, Robins JM. Estimating the causal effect of zidovudine on CD4 count with a marginal structural model for repeated measures. Stat Med. 2002;21:1689–709.

25.

Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11:550–60.

26.•

Severus E, Lipkovich I, Seemuller F, Obermeier M, Grunze H, Bernhard B, et al. The potential role of marginal structural models (MSMs) in testing the effectiveness of antidepressants in the treatment of patients with major depression in everyday clinical practice. World J Biol Psychiatry. 2013;14:386–95. A simulation experiment used to illustrate an application of marginal structural models (MSMs) in the context of the treatment of a major depressive episode.PubMedCrossRef

27.

Mortimer KM, Neugebauer R, van der Laan M, Tager IB. An application of model-fitting procedures for marginal structural models. Am J Epidemiol. 2005;162:382–8.PubMedCrossRef

Title: Double-Blind Randomized Placebo-Controlled Trials in the Treatment of Affective Disorders: Problems and Alternatives
Authors: E. Severus, M.D.
E. Laber, Ph.D.
I. Lipkovich, Ph.D.
Publication date: 01-09-2015
Publisher: Springer International Publishing
Published in: Current Treatment Options in Psychiatry / Issue 3/2015
Electronic ISSN: 2196-3061
DOI: https://doi.org/10.1007/s40501-015-0050-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Double-Blind Randomized Placebo-Controlled Trials in the Treatment of Affective Disorders: Problems and Alternatives

Opinion statement

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Opinion statement

Please log in to get access to this content

Other articles of this Issue 3/2015

Pharmacotherapy for Adolescents with Substance Use Disorders

Gender Considerations in Addiction: Implications for Treatment

Review of Psychotherapeutic Approaches for OCD and Related Disorders

Neuroscience-Informed Cognitive-Affective Training Interventions for Mood and Anxiety Disorders

Staging Models and Functional Outcomes in Bipolar Disorder: Clinical Implications

Using Optogenetics to Dissect the Neural Circuits Underlying OCD and Related Disorders